½ÃÀ庸°í¼­
»óǰÄÚµå
1595231

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : Á¦Ç°, ±¸¼º¿ä¼Ò, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Patient Blood Management Market by Product (Accessories, Instrument, Reagent & Kit), Component (Plasma, Whole Blood & Red Blood Cell), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº 2023³â¿¡ 158¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 171¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.00%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 271¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸®(PBM)´Â ¼öÇ÷ÀÌ ÇÊ¿äÇÑ È¯ÀÚÀÇ Ä¡·á¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ ´ÙÇÐÁ¦ÀûÀ̰í Áõ°Å¿¡ ±â¹ÝÇÑ Á¢±Ù¹ýÀ¸·Î, ºÒÇÊ¿äÇÑ ¼öÇ÷À» ÁÙÀ̰í, ÃâÇ÷À» ÃÖ¼ÒÈ­Çϸç, °³º° ȯÀÚÀÇ Çʿ信 ¸Â´Â ±¸Ã¼ÀûÀÎ Àü·«À» ÅëÇØ ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. °³¼±ÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº Ç÷¾× °ø±Þ ºÎÁ·, ¼öÇ÷ °ü·Ã ÇÕº´Áõ, ÀÇ·á ȯ°æÀÇ ºñ¿ë ¾ïÁ¦¶ó´Â °úÁ¦¸¦ ÇØ°áÇϱâ À§ÇØ ÇʼöÀûÀ̸ç, PBMÀº ¿Ü°ú, Á¾¾çÇÐ, ¿Ü»ó Ä¡·á, ¸¸¼º Áúȯ °ü¸® µî ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡ Àû¿ëµÇ°í ÀÖÀ¸¸ç, º´¿ø, Ŭ¸®´Ð, Ç÷¾× ÀºÇàÀÌ ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡´Â ¸¸¼º Áúȯ ¹× ¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡, ¼öÇ÷ À§Çè¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼¼Æ÷ ±¸Á¦ ¹× ´ëü Ç÷¾×°ú °°Àº ±â¼ú ¹ßÀüÀÌ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, PBM ½ÃÇàÀ» Àå·ÁÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå È®´ë¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Ç÷¾× º¸Á¸À» °­È­Çϰí, µ¥ÀÌÅÍ ¼öÁýÀ» ÀÚµ¿È­Çϰí, °³ÀÎ ¸ÂÃãÇü ÀǷḦ °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼ú¿¡ ÅõÀÚÇÔÀ¸·Î½á ½ÃÀå ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Çì¸ð±Û·Îºó ¸ð´ÏÅ͸µ°ú »õ·Î¿î ÀûÇ÷±¸ Á¶Ç÷ ÃËÁøÁ¦ °³¹ßµµ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª ³ôÀº µµÀÔ ºñ¿ë, ÀÎ½Ä ºÎÁ·, ±âÁ¸ ¼öÇ÷ °üÇà¿¡¼­ ¹þ¾î³ª´Â °Í¿¡ ´ëÇÑ °ÅºÎ°¨ µîÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. R&D¿Í Çõ½ÅÀº ºñ¿ë È¿À²ÀûÀÎ PBM ¼Ö·ç¼Ç °³¹ß°ú ÀÎ½Ä ¹× äÅ÷üÀ» ³ôÀ̱â À§ÇÑ ±³À° ÇÁ·Î±×·¥¿¡ ÁßÁ¡À» µÑ ¼ö ÀÖÀ¸¸ç, PBM µµÀÔ ÈÄ È¯ÀÚ °á°ú ºÐ¼®Àº À¯È¿¼º°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ±ÍÁßÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© ´õ ¸¹Àº ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¸¦ ²ø¾îµéÀÏ ¼ö ÀÖ½À´Ï´Ù. PBM ½ÃÀåÀÇ Æ¯¼ºÀº ¿ªµ¿ÀûÀ̸ç, ±â¼ú ¹ßÀü°ú ±ÔÁ¦ º¯È­¿¡ µû¶ó º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »óȲÀ» ¼º°øÀûÀ¸·Î ±Øº¹Çϱâ À§Çؼ­´Â ÀÌÇØ°ü°èÀÚµéÀÌ »õ·Î¿î µ¿ÇâÀ» ÆÄ¾ÇÇϰí, Çù·Â °ü°è¸¦ ±¸ÃàÇϸç, Ç÷¾× ¿À³²¿ë°ú Èñ¼Ò¼º ¹®Á¦¸¦ Àû±ØÀûÀ¸·Î ÇØ°áÇϰí, ȯÀÚ Ä¡·á¿Í ¾ÈÀü¼ºÀ» Çâ»ó½ÃŰ¸é¼­ ºñÁî´Ï½º ¼ºÀåÀ» º¸ÀåÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 158¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 171¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 271¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 8.00%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­Çϴ ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Ç÷¾×Áúȯ ±ÞÁõ¿¡ µû¸¥ ±³Åë»ç°í Áõ°¡·Î ÀÎÇÑ Ç÷¾×°ü¸® Çʿ伺 ´ëµÎ
    • ´Ù¾çÇÑ È¯ÀÚ Ç÷¾× °ü¸® °¡À̵å¶óÀÎÀÇ °¡¿ë¼º
    • ÇåÇ÷À» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀÚµ¿È­ ½Ã½ºÅÛÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • ȯÀÚ Ç÷¾× °ü¸®ÀÇ ±â¼ú ¹ßÀü
    • ÷´Ü Ç÷¾× ÀúÀå ¹× ¼öÇ÷ ÀåÄ¡ °³¹ß
  • ½ÃÀå °úÁ¦
    • ÀÇ·áÀη ºÎÁ·

Portre's Five Forces: ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå¿¡¼­°ø±Þ¾÷ü ½ÇÀû Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : Á¦Ç°º°

  • ¾×¼¼¼­¸®
    • Ç÷¾×¹é
    • ÁÖ»ç±â ¹× ¹Ù´Ã
    • ¹ÙÀÌ¾Ë ¹× Æ©ºê
  • ±â±â
    • Ç÷¾× ¹è¾ç °Ë»ç Àåºñ
      • ÀÚµ¿ Ç÷¾× ¹è¾ç ½Ã½ºÅÛ
      • ½ÇÇèÀåÄ¡ Áö¿ø
    • Ç÷¾× ó¸® Àåºñ
      • Ç÷¾× ¼¼Æ÷ ó¸® Àåºñ
      • ¿ø½ÉºÐ¸®±â
    • Ç÷¾× ÀúÀå Àåºñ
      • ÀÇ·á¿ë ³Ãµ¿°í
      • ÀÇ·á¿ë ³ÃÀå°í
    • ¼öÇ÷ Àåºñ
      • ¾ÆÆä·¹½Ã½º Àåºñ
      • ¼¼Æ÷ ±¸Á¦ ½Ã½ºÅÛ
      • ÇöóÁ ¹× ÇöóÁ ¼ººÐ ºÐ¸® Àåºñ
    • Áø´Ü ¹× °Ë»ç±â±â
      • Ç÷¾×Çü ºÐ¼® Àåºñ
      • Ç÷¾× ºÐ¼® Àåºñ
      • NGS Ç÷§Æû
      • PCR Àåºñ
  • ½Ã¾à ¹× ŰƮ
    • ¾î¼¼ÀÌ Å°Æ®
    • Ç÷¾× ¹è¾ç ¹èÁö
    • Ç÷¾×Çü ÆÇÁ¤ ½Ã¾à
    • ½½¶óÀÌµå ¿°»ö ½Ã¾à
  • ¼ÒÇÁÆ®¿þ¾î
    • Ç÷¾×ÀºÇà °ü¸® ¼ÒÇÁÆ®¿þ¾î
    • ¼öÇ÷ °ü¸® ¼ÒÇÁÆ®¿þ¾î

Á¦7Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ÇöóÁ
  • ÀüÇ÷ ¹× ÀûÇ÷±¸

Á¦8Àå ȯÀÚ Ç÷¾× °ü¸® ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Ç÷¾×ÀºÇà
  • Áø´Ü Ŭ¸®´Ð ¹× º´¸®ÇÐ ¿¬±¸½Ç
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ È¯ÀÚ Ç÷¾× °ü¸® ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Asahi Kasei Medical Co. Ltd.
  • B. Braun Melsungen AG
  • Bio-Rad Laboratories, Inc.
  • Biomerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche LTD.
  • Fresenius Se & Co. KGaA
  • Grifols, S.A.
  • Haemonetics Corporation
  • Immucor, Inc.
  • LivaNova, Inc.
  • Macopharma, Inc.
  • Merck & Co., Inc.
  • Terumo Corporation
LSH

The Patient Blood Management Market was valued at USD 15.85 billion in 2023, expected to reach USD 17.10 billion in 2024, and is projected to grow at a CAGR of 8.00%, to USD 27.17 billion by 2030.

Patient Blood Management (PBM) is a multidisciplinary, evidence-based approach to optimizing the care of patients who might need transfusion. The scope of PBM involves reducing unnecessary transfusions, minimizing blood loss, and improving patient outcomes through specific strategies tailored to individual patient needs. This approach is essential as it addresses the challenges of blood supply shortages, transfusion-related complications, and cost containment in healthcare settings. PBM is applied in various medical fields, including surgery, oncology, trauma care, and chronic disease management, with hospitals, clinics, and blood banking institutions serving as primary end-users. Market growth is influenced by the rising prevalence of chronic and surgical conditions, increasing awareness about the risks of transfusion, and advances in technologies such as cell salvage and blood substitutes. Regulatory frameworks encouraging PBM practices further spur market expansion. Opportunities in the market can be seized by investing in technologies that enhance blood conservation, automate data collection, and enable personalized medicine. The development of non-invasive hemoglobin monitoring and new erythropoiesis-stimulating agents also presents opportunities. However, challenges such as high implementation costs, lack of awareness, and reluctance to deviate from traditional transfusion practices impede market growth. Research and innovation can focus on developing cost-effective PBM solutions and educational programs to increase awareness and adoption. Analyzing patient outcomes post-PBM implementation can provide valuable data on efficacy and safety, attracting more healthcare providers to the practice. The nature of the PBM market is dynamic, propelled by technological advancements and regulatory changes. Successfully navigating this landscape requires stakeholders to stay informed on emerging trends, foster collaborations, and proactively address the challenges of blood misuse and scarcity, ensuring business growth while enhancing patient care and safety.

KEY MARKET STATISTICS
Base Year [2023] USD 15.85 billion
Estimated Year [2024] USD 17.10 billion
Forecast Year [2030] USD 27.17 billion
CAGR (%) 8.00%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Patient Blood Management Market

The Patient Blood Management Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need of blood management due to rising incidences of road accidents with the surge in the prevalence of blood disorders
    • Availability of various patient blood management guidelines
    • Government initiatives encouraging blood donations
  • Market Restraints
    • High cost of the automated systems
  • Market Opportunities
    • Technology advancements in the patient blood management
    • Development of advanced blood storage and blood transfusion devices
  • Market Challenges
    • Shortage of medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the Patient Blood Management Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Patient Blood Management Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Patient Blood Management Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Patient Blood Management Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Patient Blood Management Market

A detailed market share analysis in the Patient Blood Management Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Patient Blood Management Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Patient Blood Management Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Patient Blood Management Market

A strategic analysis of the Patient Blood Management Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Patient Blood Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Bio-Rad Laboratories, Inc., Biomerieux SA, Danaher Corporation, F. Hoffmann-La Roche LTD., Fresenius Se & Co. KGaA, Grifols, S.A., Haemonetics Corporation, Immucor, Inc., LivaNova, Inc., Macopharma, Inc., Merck & Co., Inc., and Terumo Corporation.

Market Segmentation & Coverage

This research report categorizes the Patient Blood Management Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Accessories, Instrument, Reagent & Kit, and Software. The Accessories is further studied across Blood Bag, Syringe & Needle, and Vial & Tube. The Instrument is further studied across Blood Culture Screening Device, Blood Processing Device, Blood Storage Device, Blood Transfusion Device, and Diagnostic & Testing Instrument. The Blood Culture Screening Device is further studied across Automated Blood Culture System and Supporting Laboratory Equipment. The Blood Processing Device is further studied across Blood Cell Processor and Centrifuges. The Blood Storage Device is further studied across Medical Freezer and Medical Refrigerator. The Blood Transfusion Device is further studied across Apheresis Machine, Cell Salvage System, and Plasma & Plasma Component Separator. The Diagnostic & Testing Instrument is further studied across Blood Grouping Analyzer, Hematology Analyzer, NGS Platform, and PCR Instrument. The Reagent & Kit is further studied across Assay Kit, Blood Culture Media, Blood Typing Reagent, and Slide Staining Reagent. The Software is further studied across Blood Bank Management Software and Transfusion Management Software.
  • Based on Component, market is studied across Plasma and Whole Blood & Red Blood Cell.
  • Based on End User, market is studied across Blood Bank, Diagnostic Clinic & Pathology Lab, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need of blood management due to rising incidences of road accidents with the surge in the prevalence of blood disorders
      • 5.1.1.2. Availability of various patient blood management guidelines
      • 5.1.1.3. Government initiatives encouraging blood donations
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the automated systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Technology advancements in the patient blood management
      • 5.1.3.2. Development of advanced blood storage and blood transfusion devices
    • 5.1.4. Challenges
      • 5.1.4.1. Shortage of medical professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Patient Blood Management Market, by Product

  • 6.1. Introduction
  • 6.2. Accessories
    • 6.2.1. Blood Bag
    • 6.2.2. Syringe & Needle
    • 6.2.3. Vial & Tube
  • 6.3. Instrument
    • 6.3.1. Blood Culture Screening Device
      • 6.3.1.1. Automated Blood Culture System
      • 6.3.1.2. Supporting Laboratory Equipment
    • 6.3.2. Blood Processing Device
      • 6.3.2.1. Blood Cell Processor
      • 6.3.2.2. Centrifuges
    • 6.3.3. Blood Storage Device
      • 6.3.3.1. Medical Freezer
      • 6.3.3.2. Medical Refrigerator
    • 6.3.4. Blood Transfusion Device
      • 6.3.4.1. Apheresis Machine
      • 6.3.4.2. Cell Salvage System
      • 6.3.4.3. Plasma & Plasma Component Separator
    • 6.3.5. Diagnostic & Testing Instrument
      • 6.3.5.1. Blood Grouping Analyzer
      • 6.3.5.2. Hematology Analyzer
      • 6.3.5.3. NGS Platform
      • 6.3.5.4. PCR Instrument
  • 6.4. Reagent & Kit
    • 6.4.1. Assay Kit
    • 6.4.2. Blood Culture Media
    • 6.4.3. Blood Typing Reagent
    • 6.4.4. Slide Staining Reagent
  • 6.5. Software
    • 6.5.1. Blood Bank Management Software
    • 6.5.2. Transfusion Management Software

7. Patient Blood Management Market, by Component

  • 7.1. Introduction
  • 7.2. Plasma
  • 7.3. Whole Blood & Red Blood Cell

8. Patient Blood Management Market, by End User

  • 8.1. Introduction
  • 8.2. Blood Bank
  • 8.3. Diagnostic Clinic & Pathology Lab
  • 8.4. Hospital

9. Americas Patient Blood Management Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Patient Blood Management Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Patient Blood Management Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Asahi Kasei Medical Co. Ltd.
  • 3. B. Braun Melsungen AG
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Biomerieux SA
  • 6. Danaher Corporation
  • 7. F. Hoffmann-La Roche LTD.
  • 8. Fresenius Se & Co. KGaA
  • 9. Grifols, S.A.
  • 10. Haemonetics Corporation
  • 11. Immucor, Inc.
  • 12. LivaNova, Inc.
  • 13. Macopharma, Inc.
  • 14. Merck & Co., Inc.
  • 15. Terumo Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦